On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Innovating on Numerous Fronts with DehydraTECH Drug Delivery Platform

  • Lexaria Bioscience is focusing on its unique technology for the delivery of bioactive compounds
  • The company’s concentration on oral ingestion results in an option that often healthier than other delivery methods
  • Its DehydraTECH technology has potential applications for nicotine absorption

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) focuses on technology for the improved delivery of bioactive compounds. Its DehydraTECH drug delivery platform fosters healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. The company’s process changes the way edible cannabinoids enter the body (http://ibn.fm/CB41E). A drug delivery innovator, Lexaria Bioscience is headquartered in Kelowna, British Columbia.

Lexaria’s technology has been shown to be effective in numerous global studies, significantly assisting rapidity and quantity of absorption for a range of lipophilic (fat-soluble), bioactive molecules. In essence, the company disrupts the manner in which cannabinoids enter the bloodstream through the gastrointestinal tract (http://ibn.fm/CsUCz). Lexaria’s emphasis on oral ingestion provides a practical and often healthier option to other delivery methods for bioactive substances used extensively today. This includes inhalational delivery via smoking.

The DehydraTECH platform masks taste, lessens the time of onset and increases bio-absorption by 5-10 times. The technology is patent protected for cannabidiol and all other non-psychoactive cannabinoids. Lexaria has patents pending for THC, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine, other psychoactive cannabinoids and other molecules. These patents apply to manifold consumer/pharma product dosage forms and include food liquid emulsions, capsules, tablets and more.

The Lexaria Hemp Co. holds exclusive international rights to the Lexaria patent portfolio related to hemp-based applications. Moreover, its Canadian subsidiary, Lexaria CanPharm Corp., owns exclusive international rights to Lexaria’s intellectual property that’s applicable to psychotropic bioactive molecules, which act upon human CB1 and CB2 receptors in those global geographic areas where it is permissible to do so (http://ibn.fm/d2roZ).

Lexaria Bioscience’s business model involves developing and out-licensing its DehydraTECH platform to third-party partners/distributors (http://ibn.fm/Bx1uI). In addition, its business model involves the sale of Lexaria-developed and joint venture products. The company’s product sales include hemp oil-based CBD (cannabidiol) offerings. Its TurboCBD hemp oil capsules contain ginseng and ginkgo to promote better focus and memory and have been evaluated in clinical tests.

Lexaria’s product sales additionally include ViPova-branded premium teas. These teas deliver cannabidiol in a number of flavors and have been available for several years, showcasing Lexaria’s leadership position in beverage formulations.

Lexaria Bioscience has a collaborative research agreement with Canada’s National Research Council. This research agreement is to investigate opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions (http://ibn.fm/UP5RO).

Lexaria Bioscience has engaged in research regarding the use of its technology for nicotine absorption, relating to the nicotine industry. It has partnered, via wholly owned subsidiary Lexaria Nicotine LLC, with one of the world’s largest tobacco companies to drive innovation in oral, reduced risk nicotine consumer products using the patented DehydraTECH drug delivery platform (http://ibn.fm/IHDmy). Lexaria Nicotine aims to perform a wide-ranging series of clinical investigations of oral forms of nicotine delivery, funded by its partner, employing Lexaria’s patented DehydraTECH technology.

Lexaria Bioscience continues its R&D for the improved delivery of bioactive compounds. The company offers investors the potential to earn ROI from its disruptive technology in the emerging market of low cost edibles. Lexaria continues to advance its technology that enables consumer benefits and the lowest cost-per-serving.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at www.ibn.fm/LXRP

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered